2025-08-14 - Analysis Report
Okay, here's a report analyzing Johnson & Johnson (JNJ) based on the provided data.

## Johnson & Johnson (JNJ) Stock Analysis

**JNJ: A global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.**

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 17.37%
*   **VOO Cumulative Return:** 86.23%
*   **Cumulative Return Difference:** -56.5%
*   **Historical Deviation Range:** Max 33.8%, Min -68.2%
*   **Relative Deviation:** 11.5 (Indicates JNJ's current underperformance relative to VOO is near the lower end of its historical range.)

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period. The relative deviation suggests this underperformance is close to the worst it has been historically.

**Alpha/Beta Analysis:**

| Year      | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
| :---------- | :---- | :---- | :----- | :---- | :------ |
| 2015-2017 | -1.0% | 0.0%  | -4.0%  | -0.9 | 336.5  |
| 2016-2018 | -9.0% | 56.5% | -4.0%  | -0.0 | 310.8  |
| 2017-2019 | 7.0%  | 56.5% | -16.0% | -0.1 | 351.3  |
| 2018-2020 | 22.0% | 58.6% | -5.0%  | -0.0 | 379.0  |
| 2019-2021 | 35.0% | 59.4% | -14.0% | -0.0 | 412.0  |
| 2020-2022 | 12.0% | 61.3% | 5.0%   | 0.1  | 425.4  |
| 2021-2023 | -9.0% | 61.3% | -29.0% | 0.5  | 377.5  |
| 2022-2024 | -28.0%| 61.3% | -55.0% | 0.3  | 348.3  |
| 2023-2025 | 4.0% | 70.1% | -48.0% | 0.1  | 420.1  |

**Analysis:**

*   **Alpha:**  Alpha is consistently negative, indicating JNJ has underperformed its benchmark (VOO) on a risk-adjusted basis for most periods.  The recent years show a significant negative alpha.
*   **Beta:** Beta is generally low (close to zero in many periods), suggesting JNJ's price movements are not highly correlated with the overall market. This indicates lower volatility and defensive characteristics.
*   **CAGR:** The Compound Annual Growth Rate is volatile, swinging from negative to positive territory. Recent periods show more negative CAGR.
*   **MDD:** The Maximum Drawdown is increasing over time, which is a concern.

### 2. Recent Stock Price Movement

*   **Current Price:** 174.42
*   **Previous Close:** 172.78
*   **Change:** 0.95
*   **5-Day Moving Average:** 173.18
*   **20-Day Moving Average:** 168.89
*   **60-Day Moving Average:** 159.28

**Analysis:** JNJ's stock price is above all three moving averages, indicating a potential short-term upward trend. The recent price increase compared to the previous close also supports this.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3234 (Low Risk)
*   **RSI:** 61.43 (Approaching overbought territory)
*   **PPO:** 0.1004
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Deviation Change:** 0.0 (Neutral)
*   **Expected Return:** -137.7% (Significant underperformance vs. S&P 500 over a long-term investment horizon)

**Analysis:**

*   The MRI indicates low market risk, which could suggest a stable environment for JNJ.
*   The RSI is nearing overbought levels, which could signal a potential pullback.
*   The Hybrid Signal suggests a cautious buying opportunity, advising to invest only 80% of available cash.
*   The Expected Return is extremely negative, indicating a very pessimistic outlook for JNJ's long-term performance relative to the S&P 500.
*   The recent price change suggests a slight positive movement.

### 4. Recent News & Significant Events

*   **2025-08-10:** Major business developments, regulatory changes, or market events.
*   **2025-08-12:** Notable stock volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-08-13:** Analysts discussing performance and outlook in the context of industry trends and global economic factors.
*   **2025-08-14:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news suggests JNJ is experiencing significant events that are affecting its stock price. The volatility, along with analyst discussions, indicates a period of uncertainty and potential opportunity. Investors should monitor these developments closely.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue    |
| :---------- | :---- | :---------- |
| 2025-07-24 | 2.30 | 23.74 B\$  |
| 2025-04-23 | 4.57 | 21.89 B\$  |
| 2024-10-23 | 1.12 | 22.47 B\$  |
| 2024-07-25 | 1.95 | 22.45 B\$  |
| 2025-07-24 | 1.95 | 22.45 B\$  |

**Analysis:** The EPS and revenue figures have fluctuated, with a notable increase in EPS in April 2025. Revenue has remained relatively stable, but the EPS volatility warrants further investigation into the factors affecting profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :------------ | :---------- | :------------- |
| 2025-06-30 | \$23.74B  | 67.87%         |
| 2025-03-31 | \$21.89B  | 66.40%         |
| 2024-12-31 | \$22.52B  | 68.35%         |
| 2024-09-30 | \$22.47B  | 69.01%         |
| 2024-06-30 | \$22.45B  | 69.40%         |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
| :------------ | :---------- | :----- |
| 2025-06-30 | \$78.47B  | 7.06%  |
| 2025-03-31 | \$78.11B  | 14.08% |
| 2024-12-31 | \$71.49B  | 4.80%  |
| 2024-09-30 | \$70.16B  | 3.84%  |
| 2024-06-30 | \$71.54B  | 6.55%  |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, with a slight increase in the most recent quarter.
*   **Profit Margin:** Profit margins are consistently high, indicating strong operational efficiency.
*   **Equity:** Equity has increased significantly, demonstrating growth in the company's net worth.
*   **ROE:** ROE has fluctuated, with a peak in March 2025.  It reflects the profitability of the company relative to shareholder equity.

### 7. Overall Analysis

Based on the data provided, Johnson & Johnson (JNJ) exhibits the following characteristics:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period, and the expected return suggests this trend may continue.
*   **Defensive Characteristics:**  Low Beta values suggest JNJ's stock is less volatile and less correlated with the broader market, which could be attractive to risk-averse investors.
*   **Financial Stability:** The company maintains strong profit margins and increasing equity, indicating financial health.
*   **Market Uncertainty:** Recent news suggests ongoing developments affecting the stock, leading to volatility.
*   **Mixed Signals:** While the stock price is currently trending upwards and the MRI indicates low risk, the RSI is approaching overbought levels, and the hybrid signal advises caution.

**Conclusion:**

JNJ presents a complex picture.  While it demonstrates financial stability and defensive characteristics, its significant underperformance relative to the S&P 500 and the highly negative expected return are major concerns. The recent volatility and significant events warrant close monitoring.  The current "Cautious Buy" recommendation should be approached with skepticism, and investors should conduct thorough due diligence before making any investment decisions. The company needs to address the factors causing its underperformance and improve its outlook for long-term growth.
